Theratechnologies Inc.

165 articles with Theratechnologies Inc.

• RareChannels Announces New Chief Commercial Advisor

  3/6/2019

  Carol J. Dickerson, Pharm D, Founder & CEO of CCA Channels, Inc, announces the addition of Lyne Fortin, former Senior Vice-President & Chief Commercial Officer of Theratechnologies Inc., as RareChannels Chief Commercial Advisor.

• Theratechnologies Announces Financial Results for the Third Quarter of 2018

  10/4/2018

  Record third quarter net sales of $17,714,000, up 58% from the same quarter last year

• Pharmacokinetic Profile of Trogarzo™ Presented at IDWeek

  10/3/2018

  Theratechnologies Inc. is pleased to announce that pharmacokinetic data from the pivotal phase III clinical trial for Trogarzo™ (ibalizumab-uiyk) injection will be presented tomorrow at IDWeek™ in San Francisco.

• 

  New CDC Director Pledges to Take on AIDS and Opioid Epidemics

  3/30/2018

  Days after being tapped to helm the U.S. Centers for Disease Control and Prevention, Dr. Robert Redfield predicted the AIDs epidemic can be defeated within the next three to seven years and the challenges of the opioid crisis can also be brought “to its knees.”

• Option Care Selected as the Home and Alternate Site Infusion Provider for Newly Approved Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection

  3/8/2018

  Option Care Enterprises, Inc. has been selected by Theratechnologies Inc. as an infusion provider for Trogarzo™ (ibalizumab-uiyk) Injection, an intravenous (IV) infusion for the treatment of multidrug resistant human immunodeficiency virus type 1 (HIV-1) infections.

• 

  FDA Greenlights New Treatment for Multi-Drug Resistant HIV-1

  3/7/2018

  The U.S. Food and Drug Administration has approved Trogarzo (ibalizumab), the first HIV-1 inhibitor for patients with multi-drug resistant HIV-1.

• Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1

  3/6/2018

  First HIV treatment approved with a new mechanism of action in more than 10 years

• Theratechnologies Announces Financial Results for Fiscal Year 2017

  2/7/2018

  Record revenue from net sales of $42.8 million, up 16% from previous year.

• Theratechnologies to Announce Financial Results for Fiscal Year 2017

  1/30/2018

  A conference call will be held on February 7, 2018 at 8:30 a.m. (ET) to discuss the results.

• Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018

  11/14/2017

  In a notice received today by TaiMed from the FDA, the Prescription Drug User Fee Act ("PDUFA") target action date has been extended to April 3, 2018.

• Theratechnologies Announces 48-Week Efficacy And Safety Results For Ibalizumab Presented At IDWeek 2017

  10/4/2017

• Theratechnologies Announces 48-Week Efficacy And Safety Results For Ibalizumab Presented At IDWeek 2017

  10/4/2017

• Theratechnologies Announces New Findings With The Investigational Antiretroviral Ibalizumab And With EGRIFTA (Tesamorelin For Injection)

  7/24/2017

• Theratechnologies Partner Submits Biologics License Application For HIV Monoclonal Antibody And Long-Acting Investigational Antiretroviral Ibalizumab

  5/4/2017

• Theratechnologies Announces Comparative PK Data On The Intramuscular And Intravenous Administration Of The Monoclonal Antibody And Long-Acting Investigational Antiretroviral Ibalizumab

  2/16/2017

• Theratechnologies Announces New Data From The Pivotal Phase III Trial Of HIV Monoclonal Antibody And Long-Acting Investigational Antiretroviral Ibalizumab

  2/15/2017

• Theratechnologies Announces Results From The Last Pivotal Phase III Trial Of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab

  11/10/2016

• Theratechnologies Release: Results Of HIV Biologic And Long-Acting Investigational Antiretroviral Ibalizumab To Be Presented In Late-Breaker Session At IDWeek 2016

  10/28/2016

• Theratechnologies To Announce Financial Results For The Second Quarter of 2016

  6/28/2016

• Theratechnologies Says 82.5% of Patients Achieved Primary Endpoint in Phase III Ibalizumab Trial

  5/24/2016